1. Home
  2. PSEC vs DBVT Comparison

PSEC vs DBVT Comparison

Compare PSEC & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prospect Capital Corporation

PSEC

Prospect Capital Corporation

N/A

Current Price

$2.69

Market Cap

1.3B

Sector

Finance

ML Signal

N/A

DBVT

DBV Technologies S.A.

N/A

Current Price

$23.22

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PSEC
DBVT
Founded
2004
2002
Country
United States
France
Employees
N/A
90
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
PSEC
DBVT
Price
$2.69
$23.22
Analyst Decision
Sell
Buy
Analyst Count
1
7
Target Price
$2.50
$31.75
AVG Volume (30 Days)
4.1M
186.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
20.23%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,151,000.00
Revenue This Year
N/A
$65.50
Revenue Next Year
N/A
$47.02
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.45
$3.91
52 Week High
$4.36
$26.19

Technical Indicators

Market Signals
Indicator
PSEC
DBVT
Relative Strength Index (RSI) 40.74 57.72
Support Level $2.55 $20.23
Resistance Level $2.71 $23.47
Average True Range (ATR) 0.09 1.26
MACD -0.02 0.08
Stochastic Oscillator 8.75 83.87

Price Performance

Historical Comparison
PSEC
DBVT

About PSEC Prospect Capital Corporation

Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: